Literature DB >> 7969970

Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.

S J Khoury1, C R Guttmann, E J Orav, M J Hohol, S S Ahn, L Hsu, R Kikinis, G A Mackin, F A Jolesz, H L Weiner.   

Abstract

We followed 18 multiple sclerosis patients clinically and with repeated brain MRIs with and without gadolinium for over 1 year. Clinical evaluations included scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and the Ambulation Index (AI) scale. There was a significant correlation between the change in EDSS or AI and the change in number of lesions on MRI and between cumulative number of lesions on MRI and cumulative change in EDSS or AI. Our findings support the validity of MRI as a measure of clinical activity and potentially as an objective quantitative outcome measure for assessing response to therapy.

Entities:  

Mesh:

Year:  1994        PMID: 7969970     DOI: 10.1212/wnl.44.11.2120

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Epidemiology of disabling neurological disease: how and why does disability occur?

Authors:  D T Wade
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

2.  MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.

Authors:  M L Gawne-Cain; J I O'Riordan; A Coles; B Newell; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

3.  A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.

Authors:  M Lai; T Hodgson; M Gawne-Cain; S Webb; D MacManus; W I McDonald; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

Review 4.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

5.  Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.

Authors:  T Koudriavtseva; A J Thompson; M Fiorelli; C Gasperini; S Bastianello; A Bozzao; A Paolillo; A Pisani; S Galgani; C Pozzilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

6.  An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.

Authors:  Linda Ottoboni; Brendan T Keenan; Pablo Tamayo; Manik Kuchroo; Jill P Mesirov; Guy J Buckle; Samia J Khoury; David A Hafler; Howard L Weiner; Philip L De Jager
Journal:  Sci Transl Med       Date:  2012-09-26       Impact factor: 17.956

7.  The treatment of chronic progressive multiple sclerosis with cladribine.

Authors:  E Beutler; J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

8.  The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

Authors:  B Koçer; S Yildirim-Gürel; E T Tali; C Irkeç; S Işik
Journal:  Neuroradiology       Date:  2004-03-04       Impact factor: 2.804

Review 9.  Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Authors:  Florian Deisenhammer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 10.  Multiple sclerosis.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.